Dynamic DNA-Encoded Library Technology: Discovery of Kinesin 1 Activators and Inhibitors

Michael Thompson1, Francesco Reddavide1, Stephan Heiden1, Meiyung Cui2, Till Korten2, Anna Sojkà2, Jannes Hauptstein2, Stefan Diez2 and Yixin Zhang2

1) DyNAbind GmbH, Tatzberg 47, 01307 Dresden
2) Technische Universität Dresden, 8 CUBE Center for Bioengineering, Tatzberg 41, 01307 Dresden

DNA-Encoded Library Discovery: Finding the Needle in the Haystack

DNA-Encoded Library (DEL) technology is an elegant approach to the needle-in-a-haystack problem of drug discovery. Running a DEL selection is like bringing a magnet to your haystack: up to billions of different molecules can be simultaneously interrogated against a protein target of interest. By tagging each molecule in the collection with a unique DNA barcode, their identities can be revealed after sequencing the DNA tags of binding molecules eluted from a binding assay. Due to this massive throughput and no need for a target-specific activity or functional assay, a DEL campaign can be completed at 10 times the speed of a traditional high-throughput screen.

Increasing DEL Reliability

DyNAbind’s Dynamic Library technology was designed to increase the reliability of DEL by improving signal-to-noise ratio and allowing a higher standard of library quality control. The technology is based on combining sublibraries of DNA-tagged molecular moieties. Via a universal complementary Fragment pairs randomly assemble. Combining fragments in this way offers new chemical diversity while still maintaining quality control, as each fragment DNA conjugate is individually purified and validated. This universal binding region is, however, engineered to be intrinsically unstable, so that fragment pairs are constantly reshuffling themselves, until stabilized by binding to the target protein. In this way, the most strongly binding molecules are enriched, improving signal-to-noise ratio.

Dynamic Fragment Pair Reshuffling

The advantages of the Dynamic Library architecture are clear; in head-to-head comparisons against older library designs that don’t allow dynamic reshuffling, the Dynamic Library shows over 30-fold improved signal-to-noise ratio with less instances of false positive hits.

Med-Chem Focused Library Design

Taking full advantage of improvements in DNA architecture requires the selection of library members which offer maximized chemical diversity while avoiding promiscuous, toxic or reactive substructures. At the same time, care must be taken to avoid ‘molecular obesity’ and remain in credible chemical space that actually represents good starting points for medicinal chemistry work.

From Selection to Initial Functional Validation on Kinesin 1

Kinesins are motor proteins which transport cellular cargo by moving along microtubules. Among other things, they play a role in axonal transport and successful mitotic spindle function during cell division. Due to these crucial functions, kinesin activity has been implicated in a wide range of diseases, including neurodegenerative conditions such as ALS and cancer. Though these proteins are attractive targets, drugging them has been classically difficult due to the multifunctional nature of the proteins, which makes specificity crucial. As such, new chemical starting points are always in demand. Here, we focused on screening our fragment DEL collection against a truncated version kinesin 1 which contains the motor domain.

We screened our Dynamic Dual-Fragment DEL set against the kinesin-1 motor construct in multiple conditions and were able to successfully identify multiple trending chemical structures. The plots below display the counts of paired fragments identified from the selection and sequencing. Unfortunately, due to continuing follow-up work and potential pending patent applications, no structures can be revealed at this time.

Hit Triage and Functional Validation

Fortunately, our collaboration partners in the Stefan Diez lab had already developed a novel functional readout for kinesin-1 activity, which allowed us to proceed directly to functional validation. With computational assistance, we selected an initial set of six structurally distinct hit compounds and prepared them off-DEL for follow up study.

About DyNAbind

DyNAbind GmbH is a privately held company dedicated to increasing the throughput, reliability and scope of DEL drug discovery. Our team of chemists, biologists and bioinformaticians has built a discovery pipeline that’s effective not only for more reliable discovery of medicinal chemistry starting points, but also for optimization of existing binders and affinity or specificity maturation.

We offer risk-minimized partnership opportunities for both industry and academia-based groups, where the majority of payments are based entirely on the success of our drug discovery programs and future development of hit-derived compounds. To date, we’ve worked on a number of target classes – from classical enzymes to more traditionally challenging protein-protein interactions, GPCRs and even motor proteins. DyNAbind’s library collection is always growing, and currently contains over 125 million different structures ready to deploy against your target.

From April 2019, DyNAbind is proud to offer a portion of our Dynamic Fragment DEL as a kit, available exclusively through MilliporeSigma. Containing ~400,000 fragment pairs, this kit provides information on potential target tractability and generate supporting data for grant or other funding applications. For groups lacking the funding for a traditional DEL discovery partnership, this kit offers a novel entry into the world of DEL drug discovery!

www.dynabind.com
info@dynabind.com

References